Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

jpifer 5 posts  |  Last Activity: Jun 6, 2016 7:14 PM Member since: Oct 5, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Plaintiff
    argues
    that
    CEL-SCI’s
    claims
    fit
    within
    the
    exclusion
    of
    the
    policy
    because
    they
    are
    based
    on
    PharmaNet’s
    delays
    and
    failure
    to
    complete
    the
    trial.
    Navigators
    concedes
    that,
    but
    for
    the
    exclusion,
    the
    claim
    could
    be
    included
    under
    the
    policy
    as
    a
    “professional
    liability
    claim”
    for
    a
    “wrongful
    act.”
    According
    to
    Navigators,
    PharmaNet’s
    failings
    created
    delays
    and
    setbacks
    in
    the
    study,
    ultimately
    causing
    CEL-SCI
    to
    find
    a
    new
    entity
    to
    “rescue
    and
    complete”
    the
    trial.
    It
    is
    irrelevant,
    according
    to
    Navigators,
    that
    failure
    to
    complete
    the
    task
    may
    have
    resulted
    from
    negligence,
    because
    ultimately
    the
    damages
    stem
    from
    delay,
    and
    the
    nature
    of
    the
    damages
    determines
    whether
    there
    is
    an
    obligation
    to
    defend.
    See
    L.C.S.,
    Inc.
    v.
    Lexington
    Ins.
    Co,
    371
    N.J.
    Super.
    482,
    491
    (App.
    Div.
    2004).
    Navigators
    cites
    to
    a
    number
    of
    passages
    from
    the
    ASOC
    that
    emphasize
    delay;
    for
    example:
    416.
    As
    set
    forth
    below,
    PharmaNet
    repeatedly
    breached
    the
    MSA
    and
    the
    IPA
    through
    its
    reckless
    mismanagement
    of
    the
    Phase
    III
    Trial
    including
    the
    following:
    (i)
    failing
    to
    ensure
    site
    selection
    and
    patient
    enrollment
    milestones
    were
    met;
    (ii)
    proposing,
    vetting,
    and
    contracting
    with
    unqualified
    study
    sites;
    (iii)
    assigning
    inexperienced
    managerial
    personnel
    that
    were
    not
    dedicated
    solely
    to
    the
    Phase
    III
    Trial;
    (iv)
    insufficiently
    training
    study
    site
    personnel;
    and
    (v)
    recklessly
    abandoning
    its
    contractual
    obligations,
    professional
    standards
    of
    care,
    GCP,
    and
    FDA
    regulations
    in
    managing,
    supervising,
    and
    monitoring
    the
    Phase
    III
    Trial.
    PharmaNet’s
    material
    failure
    to
    comply
    with
    its
    obligations
    under
    the
    MSA
    and
    the
    IPA,
    and
    failure
    to
    prevent
    and
    correct
    the
    myriad
    of
    avoidable
    GCP
    violations,
    were
    the
    direct
    cause
    of
    the
    continuous
    delays
    and
    failures
    that
    metastasized
    during
    PharmaNet’s
    tenure
    as
    CR0
    for
    the
    Phase
    III
    Trial
    and
    as
    a
    result
    left
    CEL-SCI
    with
    only
    a
    small
    fraction
    of
    the
    target
    patient
    enrollment
    three
    years
    after
    it
    retained
    PharmaNet.
    PharmaNet’s
    repeated
    breaches

  • jpifer@ymail.com by jpifer Jun 1, 2016 10:09 PM Flag

    ..Those that wish/hope for high numbers of cancer patients, when reality hits home, their the first ones praying for a cure......

  • Reply to

    TOMORROWS CONFERENCE,

    by wrkngitout Jun 1, 2016 1:30 PM
    jpifer@ymail.com jpifer Jun 1, 2016 4:28 PM Flag

    orphan drug status means ya don't technically have to achieve the "number" to be accepted for submission....by the way, the original number was 500...As far as I'm concerned..the number has already been achieved.......GLTA

  • Reply to

    NEW CLINICAL CENTERS ADDED,

    by wrkngitout Jan 28, 2016 7:39 AM
    jpifer@ymail.com jpifer Jan 28, 2016 10:34 AM Flag

    ..market cap should be anywhere from 600 mill to 1 bill+...$5-$10...buy-out could also happen..cheers

    Sentiment: Strong Buy

  • ..put on the company if we have a very successful clinical trial...could be bought-out before trials end..

CVM
0.4155-0.0095(-2.24%)10:06 AMEDT